ClinicalTrials.gg
CompletedNCT05708274Updated Dec 8, 2025

Pharmacological Agents for Chronic Spinal Cord Injury (SCI)

A Phase 1 interventional study of CPH + hand training and CD-LD + hand training in Spinal Cord Injuries, sponsored by Bronx VA Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Bronx VA Medical Center · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 968 studies in Spinal Cord Injuries with a site in United States — 249 open to participants now, 308 under way, 7 of them phase 3. Spinal Cord Injuries · United States.

Enrollment
389th of 836
25 · median 24
Started
2023
with 56 others
Phase 1
63 of 968
19 open now
Registered
746th of 968
by date

Among the 968 studies in Spinal Cord Injuries with a site in United States, this one is the 389th largest by enrollment of the 836 interventional ones that give a count, is one of 57 that started in 2023, is one of 63 in phase 1, and was the 746th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

249 of the 968 studies in Spinal Cord Injuries with a site in United States are open now. Recruiting first, the newest first:

244 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 968 studies in Spinal Cord Injuries with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the short-term effects of 3 approved FDA drugs (cyproheptadine (CPH), carbidopa-levodopa (CD-LD), and atomoxetine (ATX)) on motor responses when delivered in combination with hand training exercises in people with chronic spinal cord injury. The goal is to learn how to better strengthen connections between the brain and spinal cord after spinal cord injury, and if this connection is improved by one(or more) of the drugs. Multiple aspects of nerve transmission and muscle response will be measured via noninvasive brain and spinal cord stimulation, along with motor performance (dexterity and strength).

Read the detailed description

Research will take place at the James J. Peters VA Medical Center (JJPVAMC), Bronx, NY. There are seven visits in total, including an initial evaluation and clinical assessment session. Each visit will last roughly 5 hours or less. We plan to enroll 28 participants with spinal cord injury over a two-year period.

The study is designed as a double-blind, placebo-controlled, single-dose, randomized crossover investigation involving four study drug visits (CPH, CD-LD, ATX, or placebo).

The same participants will partake in all four interventions in randomized order with at least 1-week washout representative of greater than 5x drug half-life; to avoid accumulative effects. To reduce potential learning effects from motor training and task-related outcome measurements, participants will partake in two motor training practice sessions prior to commencing the experiments for task familiarity.

This study will consist of electromyography (surface recordings of muscle activity), peripheral nerve stimulation, transcranial magnetic brain stimulation (TMS), and transcutaneous electrical spinal cord stimulation (TSCS), targeting the hand/arm muscles.

Though it is unlikely given the single-dose nature, participants may experience side effects following drug administration. Prior to consenting, all volunteers will undergo a comprehensive pre-screening evaluation including blood tests to ensure there are no contraindications.

Please note, there is no expectation of long-term benefit from this study.

03

Conditions studied

  • Spinal Cord Injuries

Keywords

  • Transcranial magnetic stimulation
  • Pharmacological agents
  • Transcutaneous spinal cord stimulation
  • Hand exercise
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 65 years of age; clinically stable chronic (> 12 months) SCI at or above C8 spinal segment;
  • Motor-incomplete with a score of 2 or more (out of 5) on manual muscle testing (MMT) of finger extension, finger flexion, or finger abduction in left or right hand(s); or able to perform thumb-index finger pinch of the left or right hand;
  • Detectable stimulation-evoked muscle responses of the left or right first dorsal interosseous (FDI) and/or abductor pollicis brevis (APB); Detectable FDI/APB surface electromyography (EMG) muscle activity during thumb-index finger pinch;
  • Must have stable: medication [≥ 30 days prior]; rehabilitation regimen [≥ 15 days prior];
  • Must be able to: abstain from alcohol, smoking and caffeine consumption on the day prior/of each experiment; abstain from recreational drugs for the entirety of the study; commit to study requirements (i.e., 7 visits); provide .

Exclusion criteria

Exclusion Criteria:

  • History of moderate or severe head trauma (loss of consciousness for greater than one hour or evidence of brain contusion or hemorrhage or depressed skull fracture on prior imaging);
  • History of other serious central or peripheral neurological injury;
  • History of implanted brain/spine/nerve stimulators, aneurysm clips, ferromagnetic metallic implants in the head (except inside mouth); cochlear implants; cardiac pacemaker/defibrillator; intracardiac lines; currently increased intracranial pressure; or other to brain stimulation or task performance;
  • Ventilator dependence or patent tracheostomy site;
  • Unstable syrinx, or multiple spinal cord lesions;
  • Unclear diagnosis; History of stroke, brain tumor, brain abscess, or multiple sclerosis;
  • Personal history of seizures; extensive family history of seizures; use of medications that lower seizure threshold (e.g., amphetamines, dalfampridine, and bupropion);
  • Use of the study medications; Use of medications known to have significant adverse interactions with the study medication as described in the manufacturers' prescribing information [14 days prior]; previous allergic reaction or to study drug(s);
  • Presence of a medical condition that represents a risk for study drug(s) administration; evidence of liver disease or clinical jaundice; neutropenia; glaucoma; gastrointestinal ulcer(s); active ; undiagnosed skin lesions; disorders; chronic infectious diseases (e.g. , or C); pregnancy or nursing mothers (a pregnancy urine test may be warranted); neurologic disorders (including a history of serious head trauma or seizures), and uncontrolled cardiovascular, metabolic, pulmonary or renal disease; premorbid, ongoing major depression or psychosis, altered cognitive status; bipolar disorder; suicidal ideation or past suicide attempts;
  • History of severe hearing problems, loss or tinnitus;
  • Presence of urinary infection, fever, pressure ulcer; or open skin lesions (shoulders or arms);
  • Recent history (\< 6 months) of recurrent autonomic dysreflexia, defined as a syndrome of sudden rise in systolic pressure greater than 20 mm Hg or diastolic pressure greater than 10 mm Hg, without rise in HR, accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, and blurry vision (closely monitored during all testing procedures);
  • Heavy alcohol consumption (greater than equivalent of 5 oz of liquor) within previous 48 hours;
  • Recent history (>1 year) of chemical substance dependency or significant psychosocial disturbance;
  • Study participation of an drug or device [60 days prior];
  • Unsuitable for study participation as determined by the study physician.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    CPH + hand training

    A single dose of Cyproheptadine (CPH) (8 mg) will be administered. Supplied as 2 over-encapsulated pills of 4 mg each.

    Drug: CPH + hand training

  • Experimental
    CD-LD + hand training

    A single dose of IR Carbidopa-levodopa (CD-LD) (50/200 mg) will be administered. Supplied as 2 over-encapsulated pills (25 mg carbidopa / 100 mg levodopa each).

    Drug: CD-LD + hand training

  • Experimental
    ATX + hand training

    A single dose of Atomoxetine (ATX) (40 mg) will be administered. Supplied as 1 over-encapsulated pill of 40 mg plus 1 placebo capsule.

    Drug: ATX + hand training

  • Placebo comparator
    Placebo + hand training

    A single dose of Placebo will be administered. Supplied as 2 gelatin capsules, identical in number, size, shape and color, filled with microcrystalline cellulose.

    Drug: Placebo + hand training

Interventions

  • DrugCPH + hand training

    Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.

  • DrugCD-LD + hand training

    Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.

  • DrugATX + hand training

    Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.

  • DrugPlacebo + hand training

    Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.

06

What researchers measure

Primary outcomes

  1. Assessing task performance (dexterity)

    Unilateral manual dexterity will be assessed using the 9-Hole Peg Test (Aim 1a).

    Time frame: Assess change from baseline to 10 minutes after completion of drug+task training.

Secondary outcomes

  1. Assessing task performance (dexterity)

    Unilateral manual dexterity will be assessed using the Box and Block Test (Aim 1a).

    Time frame: Assess change from baseline to 10 minutes after completion of drug+task training.

  2. Assessing volitional grip strength

    Maximal grip force will be measured (Aim 1b). The attempt with the highest value will be used for analysis.

    Time frame: Assess change from baseline to 10 minutes after completion of drug+task training.

  3. Assessing volitional pinch strength

    Maximal pinch force will be measured (Aim 1b). The attempt with the highest value will be used for analysis.

    Time frame: Assess change from baseline to 10 minutes after completion of drug+task training.

  4. Assessing corticospinal plasticity

    Corticospinal plasticity will be measured via single-pulse TMS recruitment curves (Aim 2a).

    Time frame: Assess change from baseline to 10 minutes after completion of drug+task training.

  5. Assessing cortical plasticity

    Short intracortical inhibition (SICI) and intracortical facilitation (ICF) will be evoked with paired-pulse TMS at various interstimulus intervals according to the methods previously employed (Murray \& Knikou, 2017).

    Time frame: Assess change from baseline to 10 minutes after completion of drug+task training.

  6. Assessing spinal plasticity

    Spinal plasticity will be measured via single-pulse TSCS recruitment curves (Aim 2b).

    Time frame: Assess change from baseline to 10 minutes after completion of drug+task training.

  7. Tracking cardiovascular responses (heart rate)

    Observed measures of heart rate (HR) (Aim 3a) will be monitored throughout.

    Time frame: Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline.

  8. Tracking cardiovascular responses (blood oxygen saturation)

    Observed measures of blood oxygen saturation (SpO2) (Aim 3a) will be monitored throughout.

    Time frame: Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline.

  9. Tracking cardiovascular responses (blood pressure)

    Observed measures of blood pressure (BP) (Aim 3a) will be monitored throughout.

    Time frame: Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline.

  10. Tracking symptoms

    Participant-reported safety questionnaire (Aim 3b) will be monitored for any symptoms felt throughout the study.

    Time frame: Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline.

  11. Tracking side effects (drug administration)

    Adverse event (AE) questionnaire (Aim 3b) related to any participant-reported experience following drug administration.

    Time frame: Assess change from end of day 1 testing to 24 hours after study completion.

  12. Tracking side effects (study testing stimulation)

    Adverse event (AE) questionnaire (Aim 3b) related to any participant-reported experience following brain and/or spinal stimulation received during the experiment.

    Time frame: Assess change from end of day 1 testing to 24 hours after study completion.

07

Study locations

1 site
  • James J. Peters Veterans Affairs Medical Center
    The Bronx, New York 10468, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified, individual-level data will be deposited to appropriate public repositories, such as Open Data Commons for Spinal Cord Injury (https://scicrunch.org/odc-sci), Figshare, or others. This will allow more powerful meta-analysis of disparate smaller studies, a need which is even more urgent in neurorehabilitation than in other fields that are more amenable to large drug studies.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Within 6 months of manuscript preparation.

Access criteria: Authorization, Informed Consent, and an appropriate written agreement limiting use of the data to the conditions described in the authorization and consent. A Data Use Agreement (DUA) will indicate adherence to any applicable Informed Consent provisions, and prohibits the recipient from identifying or re-identifying any individual whose data are included in the dataset.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Oct 2025, 33 months.

Of 40 non-industry phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 55. This study's 33 months is below that.

Counting every sponsor, half of 51 studies reached it within 36 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2022
First posted
Feb 1, 2023
StartActual
Jan 20, 2023
Primary completionActual
Oct 30, 2025
CompletionActual
Oct 30, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05708274
Lead sponsor
Bronx VA Medical Center
Responsible party
Lynda M. Murray (Assistant Professor, Bronx VA Medical Center) — Principal investigator
First posted
Feb 1, 2023
Start date
Jan 20, 2023
Primary completion
Oct 30, 2025
Completion
Oct 30, 2025
Last update
Dec 8, 2025

Study contacts

Lynda M Murray, PhD
principal investigator · Bronx VA Medical Center / James J. Peters Veterans Affairs Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion